CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir

Camilla Muccini1, Nicola Gianotti1, Riccardo Lolatto1

  • 1Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute.

AIDS (London, England)
|September 26, 2024
PubMed